首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNA6 |
| Uniprot No | P05013 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-189aa |
| 氨基酸序列 | SLDCDLPQTHSLGHRRTMMLLAQMRRISLFSCLKDRHDFRFPQEEFDGNQFQKAEAISVLHEVIQQTFNLFSTKDSSVAWDERLLDKLYTELYQQLNDLEACVMQEVWVGGTPLMNEDSILAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSSSRNLQERLRRKE |
| 预测分子量 | 25.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNA6重组蛋白的3篇参考文献概述：
1. **"Molecular cloning of human interferon α6 and its expression in E. coli"**
*作者：Henco, K., et al. (1985)*
摘要：该研究首次报道了IFNA6基因的克隆及在大肠杆菌中的重组表达，证实了重组蛋白具有抗病毒活性，并分析了其与其他IFNα亚型的序列差异。
2. **"Functional characterization of recombinant interferon α6: receptor binding and antiviral specificity"**
*作者：Fish, E.N., et al. (1990)*
摘要：通过比较IFNA6与其他IFNα亚型的受体亲和力及抗病毒效果，发现IFNA6对特定病毒(如肝炎病毒)的抑制作用显著，提示其潜在治疗应用。
3. **"IFNA6 activates distinct JAK-STAT signaling pathways in hematopoietic cells"**
*作者：Coccia, E.M., et al. (2001)*
摘要：研究利用重组IFNA6蛋白处理细胞，揭示其激活的STAT蛋白亚型与其他干扰素不同，可能影响免疫细胞分化及肿瘤微环境调控。
*注：以上文献为模拟示例，实际引用需核实具体来源及细节。*
Interferon alpha-6 (IFNA6) is a member of the type I interferon (IFN) family, a group of cytokines critical for antiviral defense, immune modulation, and antitumor activity. Type I IFNs, including multiple IFN-α subtypes (IFNA1. IFNA2. IFNA6. etc.), IFN-β, and others, signal through a common heterodimeric receptor (IFNAR1/IFNAR2) to activate the JAK-STAT pathway, inducing hundreds of interferon-stimulated genes (ISGs) that mediate diverse biological effects. IFNA6. encoded by the IFNA6 gene, shares structural homology with other IFN-α subtypes but exhibits unique receptor-binding kinetics and functional specificity. Unlike the widely studied IFNA2. IFNA6 displays lower receptor affinity but prolonged signaling, potentially influencing its therapeutic profile.
Recombinant IFNA6 protein is produced using genetic engineering techniques, typically via expression in mammalian systems (e.g., CHO or HEK293 cells) to ensure proper folding and post-translational modifications. This allows large-scale production of bioactive IFNA6 for research and clinical applications. Recombinant IFNA6 has been utilized to study subtype-specific antiviral mechanisms, immune cell activation, and tumor suppression. Its distinct signaling dynamics may offer advantages in specific contexts, such as chronic viral infections or cancers resistant to conventional IFN therapies.
Despite its potential, IFNA6 is less characterized compared to other IFN-α subtypes. Research focuses on elucidating its unique ISG induction patterns, cross-talk with other cytokines, and optimization for therapeutic use. Challenges include balancing its potent immunostimulatory effects with dose-limiting toxicities, a common issue in IFN-based therapies. Current applications span in vitro studies, preclinical models, and exploratory clinical trials, particularly in combination therapies aiming to enhance efficacy while minimizing side effects.
×
